We read with great interest the Brief Report "Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study" by Canzian et al, recently published in Arthritis & Rheumatology (1). It probably provides the largest real-life contribution on EGPA and biologic drugs. Despite the increasing evidence on the topic, including clinical trials and real life studies (2,3), identifying the most appropriate biologic treatment still represents a challenge.
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all
Caminati, Marco;Giollo, Alessandro;Senna, Gianenrico;Lunardi, Claudio
2021-01-01
Abstract
We read with great interest the Brief Report "Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study" by Canzian et al, recently published in Arthritis & Rheumatology (1). It probably provides the largest real-life contribution on EGPA and biologic drugs. Despite the increasing evidence on the topic, including clinical trials and real life studies (2,3), identifying the most appropriate biologic treatment still represents a challenge.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
